Epacadostat
Phase 2Small molecule
IncyteEpacadostat is an experimental cancer drug that works by blocking an enzyme called indoleamine 2,3-dioxygenase (IDO), which helps tumors hide from the immune system. It's being studied to help the body's immune system recognize and fight cancer cells more effectively.[1] Epacadostat is currently being investigated across 3 indications[3], with its most advanced program in Phase 2.[1]
Epacadostat is one of 86 small molecule programs targeting Locally Advanced. It is currently in Phase 2.
3
Indications
50
Total Trials
3
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
103 competitors in Endometrial Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Femara
NovartisPhase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Megace
Bristol-Myers SquibbPhase 3
Lenvima
EisaiPhase 3
Lynparza
AstraZenecaPhase 3
Depo-Provera
Eli LillyPhase 3
Tecentriq
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors4 trials
Show 1 more trial
Non-Small Cell Lung Cancer4 trials
Urothelial Carcinoma3 trials
Pembrolizumab3 trials
Epacadostat and Pembrolizumab in Patients With GIST
Terminated·—·Phase 2·NCT03291054·1 enrolled
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
Terminated·—·Phase 2·NCT03823131·14 enrolled
29 more indications
AML2 trials
Ovarian Cancer2 trials
Primary Peritoneal Cancer2 trials
Head and Neck Cancer2 trials
Squamous Cell Carcinoma2 trials
Advanced or Metastatic Solid Tumors1 trial
Esophageal Cancer1 trial
Lymphoma1 trial
Pancreatic Cancer1 trial
Glioma1 trial
Bladder Urothelial Cancer1 trial
Metastatic Melanoma1 trial
Advanced Cancers1 trial
Solid Tumor Malignancies1 trial
Patients With Advanced Solid Tumors1 trial
Nasopharyngeal Cancer1 trial
Small Cell Lung Cancer1 trial
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
Withdrawn·—·Phase 2·NCT03402880
Pancreas Cancer1 trial
Gastric Cancer1 trial
Locally Advanced1 trial
Chemotherapy1 trial
Patients With Locally Advanced Rectal Cancer1 trial
Endometrial Cancer1 trial
Advanced Malignancy1 trial
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epacadostat. EMBL-EBI & Wellcome Sanger Institute.
- [4]